date:May 07, 2013
nced AMD, also addressed the role of beta carotene as this was a part of the original AREDS formulation. A subgroup analysis of lutein and zeaxanthin and the original AREDS formulation without beta carotene as compared to the group lutein and zeaxanthin and the original AREDS formulation with beta carotene resulted in a significant risk reduction of 18 percent for progression to advanced AMD for the group receiving no beta carotene.
No beneficial or harmful effects of DHA + EPA for treatment of